Scott K Sherman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9528448/publications.pdf

Version: 2024-02-01

471061 500791 45 885 17 28 citations h-index g-index papers 46 46 46 1323 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Liver-directed surgery of neuroendocrine metastases: WhatÂisÂthe optimal strategy?. Surgery, 2016, 159, 320-335.	1.0	148
2	Pancreastatin Predicts Survival in Neuroendocrine Tumors. Annals of Surgical Oncology, 2014, 21, 2971-2980.	0.7	57
3	Medical management of metastatic medullary thyroid cancer. Cancer, 2014, 120, 3287-3301.	2.0	38
4	Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 236.	3.4	36
5	A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors. Surgery, 2014, 156, 1359-1366.	1.0	35
6	The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms. Cancer, 2020, 126, 2525-2533.	2.0	35
7	RABL6A Promotes G1–S Phase Progression and Pancreatic Neuroendocrine Tumor Cell Proliferation in an Rb1-Dependent Manner. Cancer Research, 2014, 74, 6661-6670.	0.4	32
8	Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors. Surgery, 2013, 154, 1206-1214.	1.0	31
9	Effect of BMI on Outcomes in Proctectomy. Diseases of the Colon and Rectum, 2014, 57, 608-615.	0.7	31
10	Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors. Clinical and Experimental Metastasis, 2014, 31, 935-944.	1.7	28
11	Overexpression of Membrane Proteins in Primary and Metastatic Gastrointestinal Neuroendocrine Tumors. Annals of Surgical Oncology, 2013, 20, 739-746.	0.7	27
12	Somatic alterations of CDKN1B are associated with small bowel neuroendocrine tumors. Cancer Genetics, 2015, 208, 564-570.	0.2	25
13	Limitations of somatostatin scintigraphy in primary small bowel neuroendocrine tumors. Journal of Surgical Research, 2014, 190, 548-553.	0.8	23
14	Peritoneal Metastases in Colorectal Cancer. Annals of Surgical Oncology, 2018, 25, 2145-2151.	0.7	23
15	Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial. Surgery, 2018, 164, 1223-1229.	1.0	21
16	The Chicago Consensus on peritoneal surface malignancies: Management of gastric metastases. Cancer, 2020, 126, 2541-2546.	2.0	21
17	Development of an Improved Risk Calculator for Complications in Proctectomy. Journal of Gastrointestinal Surgery, 2014, 18, 986-994.	0.9	20
18	Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors. Clinical Cancer Research, 2016, 22, 5022-5029.	3.2	20

#	Article	IF	CITATIONS
19	Surgical Management of Neuroendocrine Tumor Liver Metastases. Surgical Oncology Clinics of North America, 2021, 30, 39-55.	0.6	20
20	GIPR expression in gastric and duodenal neuroendocrine tumors. Journal of Surgical Research, 2014, 190, 587-593.	0.8	17
21	The Chicago Consensus on peritoneal surface malignancies: Management of colorectal metastases. Cancer, 2020, 126, 2534-2540.	2.0	17
22	Preoperative calcitriol reduces postoperative intravenous calcium requirements and length of stay in parathyroidectomy for renal-origin hyperparathyroidism. Surgery, 2019, 165, 151-157.	1.0	16
23	The Landmark Series: Management of Small Bowel Neuroendocrine Tumors. Annals of Surgical Oncology, 2021, 28, 2741-2751.	0.7	16
24	Metastatic Colorectal Cancers with Mismatch Repair Deficiency Result in Worse Survival Regardless of Peritoneal Metastases. Annals of Surgical Oncology, 2020, 27, 5074-5083.	0.7	15
25	BMPR1A mutations in juvenile polyposis affect cellular localization. Journal of Surgical Research, 2013, 184, 739-745.	0.8	14
26	Assessment of the Surgical Workforce Pertaining to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the United States. Annals of Surgical Oncology, 2020, 27, 3097-3102.	0.7	14
27	Differences in Short-term Outcomes Among Patients Undergoing IPAA With or Without Preoperative Radiation. Diseases of the Colon and Rectum, 2014, 57, 1188-1194.	0.7	13
28	It Is Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors. Annals of Surgical Oncology, 2021, 28, 732-741.	0.7	13
29	Small Bowel Neuroendocrine Tumors. Current Problems in Surgery, 2020, 57, 100823.	0.6	12
30	Translational Research in Endocrine Surgery. Surgical Oncology Clinics of North America, 2013, 22, 857-884.	0.6	11
31	Esophageal cancer in a family with hamartomatous tumors and germline PTEN frameshift and SMAD7 missense mutations. Cancer Genetics, 2015, 208, 41-46.	0.2	10
32	Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer. Journal of Surgical Research, 2021, 266, 104-112.	0.8	9
33	The Chicago Consensus on peritoneal surface malignancies: Standards. Cancer, 2020, 126, 2516-2524.	2.0	7
34	Estimating Surgical Risk for Patients With Severe Comorbidities. JAMA Surgery, 2018, 153, 778.	2.2	6
35	Resident involvement in postoperative conversations: an underused opportunity. Journal of Surgical Research, 2014, 190, 437-444.	0.8	4
36	The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors. Annals of Surgical Oncology, 2019, 26, 2525-2532.	0.7	4

#	Article	IF	CITATIONS
37	Progress in the Management of Pancreatic Neuroendocrine Tumors. Annual Review of Medicine, 2022, 73, .	5.0	4
38	Modern Surgical Techniques in Cytoreductive Surgery. Journal of Gastrointestinal Surgery, 2020, 24, 454-459.	0.9	3
39	Gene expression in neuroendocrine tumor liver metastases accurately distinguishes between pancreas and small bowel primary tumors. Journal of the American College of Surgeons, 2013, 217, S129.	0.2	2
40	Prospective Validation of the lowa Rectal Surgery Risk Calculator. Journal of Gastrointestinal Surgery, 2018, 22, 1258-1267.	0.9	2
41	The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors. Cancer, 2020, 126, 2561-2565.	2.0	2
42	Potential evidence of peritoneal recurrence in Stage-II colon cancer from the control arm of CALGB9581. American Journal of Surgery, 2022, 224, 459-464.	0.9	2
43	Implementation of bundled care to reduce surgical site infections after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Journal of Surgical Oncology, 2019, 120, 1044-1045.	0.8	1
44	ASO Author Reflections: Mismatch Repair and Survival in Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2020, 27, 5084-5085.	0.7	0
45	Jejunoileal Neuroendocrine Tumors. , 2021, , 157-177.		0